Adma Biologics (ADMA) EBT (2011 - 2026)
Adma Biologics' (ADMA) quarterly EBT came in at -$121.1 million in Q4 2025, down 448.75% YoY from $34.7 million in Q4 2024, and down 354.78% on a QoQ basis from $47.5 million in Q3 2025.
Adma Biologics (ADMA) EBT (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of EBT data on file, last reported at -$121.1 million in Q4 2025.
- Quarterly EBT fell 448.75% year-over-year to -$121.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1000.0 (down 100.0% YoY) and the FY2024 annual result came in at $125.7 million, changed N/A from the prior year.
- EBT eased to -$121.1 million in Q4 2025, from $47.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of $47.5 million in Q3 2025 to a low of -$121.1 million in Q4 2025.
- A 5-year average of -$63255.5 and a median of -$6.6 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT soared 1332.71% — and 2025, when it slumped 448.75%.
- Tracing ADMA's EBT over 5 years: stood at -$13.5 million in 2021, then climbed by 12.57% to -$11.8 million in 2022, then jumped by 189.84% to $10.6 million in 2023, then jumped by 227.67% to $34.7 million in 2024, then tumbled by 448.75% to -$121.1 million in 2025.
- The last three EBT figures came in at -$121.1 million (Q4 2025), $47.5 million (Q3 2025), and $40.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 50.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.24 Mn |
| Dec 31, 2025 | -121.06 Mn |
| Sep 30, 2025 | 47.52 Mn |
| Jun 30, 2025 | 40.10 Mn |
| Mar 31, 2025 | 33.45 Mn |
| Dec 31, 2024 | 34.71 Mn |
| Sep 30, 2024 | 36.75 Mn |
| Jun 30, 2024 | 35.85 Mn |
| Mar 31, 2024 | 18.40 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -11.79 Mn |
| Sep 30, 2022 | -14.89 Mn |
| Jun 30, 2022 | -13.75 Mn |
| Mar 31, 2022 | -18.17 Mn |
| Dec 31, 2021 | -13.49 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.82 Mn |